Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57... ( Other revenue 12...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share

Date:5/8/2008

>

Other revenue 12 (5) (b) 7

Total revenues 597 (5) 592

Costs and expenses

Cost of sales 300 (80) (b),(c),(d),(f) 220

Selling, general and

administrative 179 (9) (b),(d),(g) 170

Research and

development 62 - 62

Write-off of acquired

IPR&D 2 (2) (e) -

Earnings from operations 54 86 140

Interest income 11 - 11

Interest expense 42 - 42

Other (expense) income, net 1 - 1

Earnings before income

taxes and minority interest 24 86 110

Income tax expense 10 20 (h) 30

Minority interest loss (1) - (1)

Net earnings from continuing

operations 13 66 79

Net loss from discontinued

operations, net of taxes (1) 1 (a) -

Net earnings $12 $67 $79

Diluted

Earnings per common share -

continuing operations $0.12 $0.73

Earnings per common share -

discontinued operations $(0.01) $-

Net earnings per common

share - diluted $0.11 $0.73

Weighted average shares

- diluted 108 108

Summary of Adjustment Items:

Three M
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results

Post Your Comments:

Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4 Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2

[0] BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year [0] Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope [0] VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 [0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results

Other Biology Technology:Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium 2 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium 3 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium 4 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium 5 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium 6 Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2

Oncothyreon to present at BIO Investor Forum 2008 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction

Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2 Genome BC collaborates with Chile and Norway to sequence salmon genome 2 Study shows nearly 1/3 of human genome is involved in gingivitis 2 Study shows nearly 1/3 of human genome is involved in gingivitis 3 Behavioral Testing for Children Now Offered at Marianjoy 60722 1 Behavioral Testing for Children Now Offered at Marianjoy 60722 2 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 1 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 2 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 3 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 4 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 5 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 6 HeartWare International Reports Third Quarter Revenues of 247 5 Million 5998 7 USC study finds big air pollution impacts on local communities 10640 1 USC study finds big air pollution impacts on local communities 10640 2

[0] Delivering medicine directly into a tumor [0] Genome BC collaborates with Chile and Norway to sequence salmon genome [0] Study shows nearly 1/3 of human genome is involved in gingivitis

Other Biology News:New study pinpoints epicenters of Earth's imminent extinctions 2 Ancient humans brought bottle gourds to the Americas from Asia 2

Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful New study pinpoints epicenters of Earth's imminent extinctions Ancient humans brought bottle gourds to the Americas from Asia

Biology Products:

Mouse Anti-Human MCFD2 Polyclonal Antibody, Unconjugated from Novus Biologicals Rabbit Anti-Porcine Vitronectin Antibody, Unconjugated from Cosmo Bio Co., Ltd.Automation Certified Syringe Filters from Caliper Life Sciences Rabbit Anti-BMP2 Polyclonal Antibody, Unconjugated from GeneTex